Former Sanofi chief executive joins Waypoint
pharmafile | June 23, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Sanofi, Viehbacher, waypoint
The former Sanofi chief executive Christopher Viehbacher is joining Geneva-headquartered business enterprise firm Waypoint Capital as a managing partner.
Viehbacher was ousted from his role at the French pharma giant after the board lost patience with his leadership style, and replaced by Bayer chairman Oliver Brandicourt.
During Viehbacher’s six-year tenure at Sanofi it underwent quite a business transformation – most notable of which was the acquisition of Genzyme. Viehbacher served as the chairman of the board of Genzyme in Boston.
Following his departure he found another role at US science and technology R&D company PureTech sitting among its board members.
Happy with this latest move is Ernesto Bertarelli, the chairman of Waypoint, who says: “Chris is an industry leader with significant experience in acquiring companies, business development and licensing.
“In combination, this makes him the ideal person to lead Gurnet Point Capital [Waypoint’s healthcare investment fund] and to drive our distinctive value-creating investment approach.”
Viehbacher adds: “I am delighted to be joining Gurnet Point Capital and its team of outstanding healthcare experts, which we will continue to expand. It is a particular pleasure to be asked to work with Ernesto Bertarelli, who has such an outstanding track record of achievement himself in this sector.”
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
